Granted Patent
B2
US 12,398,392 · App. 18/623,612 · Granted Aug 26, 2025
Methods and compositions for modulating a genome
Inventors:
Jacob Rosenblum Rubens (Cambridge, MA); Geoffrey A. von Maltzahn (Somerville, MA); Robert James Citorik (Somerville, MA); Barrett Ethan Steinberg (Somerville, MA); Donghui Li (Somerville, MA); William Edward Salomon (West Roxbury, MA)
Assignee:
Flagship Pioneering Innovations VI, LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods and compositions for modulating a target genome are disclosed. The composition may comprise a first RNA encoding a polypeptide comprising a retrotransposase reverse transcriptase domain and a retrotransposase endonuclease domain. The composition may also comprise a second RNA comprising a sequence that binds the polypeptide and a heterologous object sequence. The composition may insert the sequence of the heterologous object sequence into a target DNA.
Claims (23)
1. A method of modifying a target DNA strand in a cell, tissue or subject, the method comprising administering a composition for modifying DNA to the cell, tissue or subject, thereby modifying the target DNA strand;
wherein the composition for modifying DNA comprises:
(a) a first engineered RNA encoding a polypeptide, wherein the polypeptide comprises (i) a reverse transcriptase domain and (ii) an endonuclease domain, wherein the polypeptide comprises the amino acid sequence SEQ ID NO: 1387, or a sequence having at least 99% identity thereto; and
(b) a second engineered RNA comprising a template RNA, wherein the template RNA comprises (i) the sequence of SEQ ID NO: 1142, or a sequence having at least 99% identity thereto, that binds the encoded polypeptide, and (ii) a heterologous object sequence; and
wherein (a) and (b) are separate RNAs.
2. The method of claim 1 , wherein the template RNA further comprises a sequence comprising at least 20 nucleotides of at least 80% identity to a target DNA.
3. The method of claim 1 , wherein the template RNA comprises:
(iii) at least 3 bases of identity to a target DNA at the 3′ end of the template RNA, and (iv) at least 3 bases of identity to the target DNA at the 5′ end of the template RNA.
4. The method of claim 1 , wherein the heterologous object sequence encodes an enzyme, a membrane protein, a blood factor, an intracellular protein, an extracellular protein, a structural protein, a signaling protein, a regulatory protein, a transport protein, or a motor protein.
5. The method of claim 1 , wherein the polypeptide further comprises one or both of a nuclear localization signal and a nucleolar localization signal.
6. The method of claim 1 , wherein the composition comprises only RNA, or comprises more RNA than DNA by an RNA:DNA ratio of at least 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1.
7. The method of claim 1 , wherein the template RNA does not encode a reverse transcriptase or an endonuclease.
8. The method of claim 1 , wherein the template RNA comprises: at least 10 bases of identity to a target DNA at the 3′ end of the template RNA, and (iv) at least 10 bases of identity to the target DNA at the 5′ end of the template RNA.
9. The method of claim 1 , wherein the template RNA further comprises the sequence of SEQ ID NO: 1265, or a sequence having at least 95% identity thereto.
10. The method of claim 1 , wherein the template RNA further comprises the sequence of SEQ ID NO: 1265, or a sequence having at least 99% identity thereto.
11. The method of claim 1 , wherein the template RNA further comprises the sequence of SEQ ID NO: 1265.
12. The method of claim 1 , wherein the template RNA further comprises the sequence of SEQ ID NO: 1142.
13. The method of claim 1 , wherein the target DNA is a genomic safe harbor (GSH) site.
14. The method of claim 1 , wherein the heterologous object sequence encodes a therapeutic polypeptide or fragment thereof.
15. The method of claim 1 , wherein the heterologous object sequence comprises a non-coding sequence or a regulatory sequence.
16. The method of claim 1 , wherein the composition comprises no more than 1%, 0.5%, 0.2%, 0.1%, 0.05%, 0.02%, or 0.01% DNA by mass or by molar amount of nucleic acid.
17. The method of claim 1 , wherein the composition is capable of modifying DNA in the absence of homologous recombination activity.
18. The method of claim 15 , wherein the regulatory sequence is a promoter.
Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 22, 2024
From: RUBENS, JACOB ROSENBLUM; VON MALTZAHN, GEOFFREY A.; CITORIK, ROBERT JAMES
To: FLAGSHIP PIONEERING, INC.
Reel/Frame 068365/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 22, 2024
From: TESSERA THERAPEUTICS, INC.
To: FLAGSHIP PIONEERING, INC.
Reel/Frame 068365/0732 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 22, 2024
From: FLAGSHIP PIONEERING, INC.
To: FLAGSHIP PIONEERING INNOVATIONS VI, LLC
Reel/Frame 068365/0821 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 22, 2024
From: STEINBERG, BARRETT ETHAN; LI, DONGHUI
To: FLAGSHIP VL58, INC.
Reel/Frame 068365/0380 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 22, 2024
From: SALOMON, WILLIAM EDWARD
To: TESSERA THERAPEUTICS, INC.
Reel/Frame 068365/0515 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 22, 2024
From: FLAGSHIP PIONEERING, INC.
To: FLAGSHIP PIONEERING INNOVATIONS VI, LLC
Reel/Frame 068365/0659 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 22, 2024
From: FLAGSHIP VL58, INC.
To: FLAGSHIP PIONEERING, INC.
Reel/Frame 068365/0668 →
Continuity (7)
Continuation
PCTUS2019048607
· Aug 28, 2019
Provisional Application
62864924
· Jun 21, 2019
Provisional Application
62850883
· May 21, 2019
Provisional Application
62725778
· Aug 31, 2018
Provisional Application
62723886
· Aug 28, 2018
References Cited (298)
US 6693086B1
· Dow et al.
· 2004
[cited by applicant]
US 8889418B2
· Zhang et al.
· 2014
[cited by applicant]
US 9267932B2
· Boeke et al.
· 2016
[cited by applicant]
US 20030121063A1
· Kazazian et al.
· 2003
[cited by applicant]
US 20070037759A1
· Deininger et al.
· 2007
[cited by applicant]
US 20100154070A1
· Xu et al.
· 2010
[cited by applicant]
US 20110171729A1
· Wang et al.
· 2011
[cited by applicant]
US 20140113375A1
· Liu et al.
· 2014
[cited by applicant]
US 20140315985A1
· May et al.
· 2014
[cited by applicant]
US 20140349400A1
· Jakimo et al.
· 2014
[cited by applicant]
US 20170275665A1
· Silas et al.
· 2017
[cited by applicant]
US 20180298391A1
· Jakimo et al.
· 2018
[cited by applicant]
US 20190177735A1
· Sederoff et al.
· 2019
[cited by applicant]
US 20220396813A1
· Feala et al.
· 2022
[cited by applicant]
US 20230131847A1
· Rubens et al.
· 2023
[cited by applicant]
US 20230235358A1
· Citorik et al.
· 2023
[cited by applicant]
US 20230242899A1
· Steinberg et al.
· 2023
[cited by applicant]
US 20230272430A1
· Bothmer et al.
· 2023
[cited by applicant]
US 20230332184A1
· Rubens et al.
· 2023
[cited by applicant]
US 20230348939A1
· Bothmer et al.
· 2023
[cited by applicant]
US 20240042058A1
· Citorik et al.
· 2024
[cited by applicant]
US 20240084334A1
· Altshuler et al.
· 2024
[cited by applicant]
US 20240200104A1
· Citorik et al.
· 2024
[cited by applicant]
US 20240247243A1
· Altshuler et al.
· 2024
[cited by applicant]
US 20240252682A1
· Altshuler et al.
· 2024
[cited by applicant]
US 20240263153A1
· Rubens et al.
· 2024
[cited by applicant]
US 20240374759A1
· Altshuler et al.
· 2024
[cited by applicant]
CN 1342758A
· 2002
[cited by applicant]
CN 105308184A
· 2016
[cited by applicant]
CN 107208078A
· 2017
[cited by applicant]
EP 1700914A1
· 2006
[cited by applicant]
EP 3448990B1
· 2021
[cited by applicant]
WO 2003064644A1
· 2003
[cited by applicant]
WO 2005049789A2
· 2005
[cited by applicant]
WO 2008072540A1
· 2008
[cited by applicant]
WO 2011064750A1
· 2011
[cited by applicant]
WO 2014093718A1
· 2014
[cited by applicant]
WO 2014150624A1
· 2014
[cited by applicant]
WO 2015035139A2
· 2015
[cited by applicant]
WO 2015191693A2
· 2015
[cited by applicant]
WO 2016028843A2
· 2016
[cited by applicant]
WO 2016036754A1
· 2016
[cited by applicant]
WO 2016065364A1
· 2016
[cited by applicant]
WO 2016201047A1
· 2016
[cited by applicant]
WO 2016205728A1
· 2016
[cited by applicant]
WO 2017059241A1
· 2017
[cited by applicant]
WO 2017123609A1
· 2017
[cited by applicant]
WO 2017137768A1
· 2017
[cited by applicant]
WO 2017151719A1
· 2017
[cited by applicant]
WO 2017173004A1
· 2017
[cited by applicant]
WO 2017173054A1
· 2017
[cited by applicant]
WO 2017180711A1
· 2017
[cited by applicant]
WO 2017186550A1
· 2017
[cited by applicant]
WO 2017197238A1
· 2017
[cited by applicant]
WO 2018027078A1
· 2018
[cited by applicant]
WO 2018049168A1
· 2018
[cited by applicant]
WO 2018071663A1
· 2018
[cited by applicant]
WO 2018089860A1
· 2018
[cited by applicant]
WO 2018165629A1
· 2018
[cited by applicant]
WO 2018176009A1
· 2018
[cited by applicant]
WO 2018218166A1
· 2018
[cited by applicant]
WO 2019051097A1
· 2019
[cited by applicant]
WO 2020014528A1
· 2020
[cited by applicant]
WO 2020047124A1
· 2020
[cited by applicant]
WO 2020082076A1
· 2020
[cited by applicant]
WO 2020186262A1
· 2020
[cited by applicant]
WO 2020191233A1
· 2020
[cited by applicant]
WO 2020191234A1
· 2020
[cited by applicant]
WO 2020191239A1
· 2020
[cited by applicant]
WO 2020191241A1
· 2020
[cited by applicant]
WO 2020191242A1
· 2020
[cited by applicant]
WO 2020191243A1
· 2020
[cited by applicant]
WO 2020191245A1
· 2020
[cited by applicant]
WO 2020191246A1
· 2020
[cited by applicant]
WO 2020191248A1
· 2020
[cited by applicant]
WO 2020191249A1
· 2020
[cited by applicant]
WO 2020191171A9
· 2020
[cited by applicant]
WO 2020191153A9
· 2020
[cited by applicant]
WO 2020252361A1
· 2020
[cited by applicant]
WO 2021016075A1
· 2021
[cited by applicant]
WO 2021080922A1
· 2021
[cited by applicant]
WO 2021102390A1
· 2021
[cited by applicant]
WO 2021178709A1
· 2021
[cited by applicant]
WO 2021178717A2
· 2021
[cited by applicant]
WO 2021178720A2
· 2021
[cited by applicant]
WO 2021178898A9
· 2021
[cited by applicant]
WO 2021248102A1
· 2021
[cited by applicant]
U.S. Appl. No. 18/282,644, filed Sep. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/280,749, filed Sep. 7, 2023.
[cited by applicant]
U.S. Appl. No. 18/563,127, filed Nov. 21, 2023.
[cited by applicant]
U.S. Appl. No. 18/690,134, filed Mar. 7, 2024.
[cited by applicant]
U.S. Appl. No. 18/595,904, filed Mar. 5, 2024.
[cited by applicant]
U.S. Appl. No. 18/590,275, filed Feb. 28, 2024.
[cited by applicant]
U.S. Appl. No. 18/690,120, filed Mar. 7, 2024.
[cited by applicant]
Fujimoto et al., “Integration of the 5′ end of the retrotransposon, R2Bm, can be complemented by homologous recombination,” Nucleic Acids Research (2004) vol. 32, No. 4, pp. 1555-1565.
[cited by applicant]
Fujiwara H., Site-specific non-LTR retrotransposons. ASMscience.org/MicrobiolSpectrum, 2015, pp. 1-16. (Year: 2015).
[cited by applicant]
Galantou RN., Cellular factors controlling human L 1 retrotransposition. Ph.D. Dissertation, 2017, Universite Cote D'Azur, France, pp. 1-175. (Year: 2017).
[cited by applicant]
García-rodríguez et al., Use of the computer-retargeted group II intron RmInt1 of Sinorhizobium meliloti for gene targeting, RNA Biology (2014) vol. 11, No. 4, pp. 391-401.
[cited by applicant]
Garneau et al., “The CRISPR-Cas bacterial immune system cleaves bacteriophage and plasmid DNA,” Nature (2010) vol. 468, pp. 67-71.
[cited by applicant]
George et al., “Analysis of the 5′ Junctions of R2 Insertions With the 28S Gene-Implications for Non-LTR Retrotransposition,” Genetics (1996) vol. 142, pp. 853-863.
[cited by applicant]
Gilbert et al., “Multiple Fates of L1 Retrotransposition Intermediates in Cultured Human Cells,” Molecular and Cellular Biology (2005) vol. 25, No. 17, pp. 7780-7795.
[cited by applicant]
Gladyshev-Rotifer et al., “rDNA-specific R9 retrotransposable elements generate an exceptionally long target site duplication upon insertion,” Gene (2009) vol. 448, pp. 145-150.
[cited by applicant]
Goodier et al., “Restricting retrotransposons—a review,” Mobile DNA (2016) vol. 7, Article 16, 30 pages.
[cited by applicant]
Govindaraju et al., “Endonuclease domain of non-LTR retrotransposons: loss-of-function mutants and modeling of the R2Bm endonuclease,” Nucleic Acids Researh (2016) vol. 44, No. 7, pp. 3276-3287.
[cited by applicant]
Govindraju A., Protein/Nucleic-Acid Structure and Sequence Requirements for Specifying Second-Strand Cleavage and Second-Strand Synthesis During the Integration of the Site-Specific Line R2Bm. Ph.D. Dissertation, The Un…
[cited by applicant]
Ha et al., “Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges,” Acta Pharmaceutica Sinica B (2016) vol. 6, Issue 4, pp. 287-296.
[cited by applicant]
Haack et al., “Cryo-EM Structures of a Group II Intron Reverse Splicing into DNA,” Cell (2019) vol. 178, pp. 612-623.
[cited by applicant]
Halperin et al., “CRISPR-guided DNA polymerases enable diversification of all nucleotides in a tunable window,” Nature (2018) vol. 560, No. 7717, pp. 248-252.
[cited by applicant]
Han et al., “Circular retrotransposition products generated by a LINE retrotransposon,” Nucleic Acids Research (2012) vol. 40, No. 21, pp. 10866-10877.
[cited by applicant]
Han, “Non-long terminal repeat (non-LTR) retrotransposons-mechanisms, recent developments, and unanswered questions,” Mobile DNA (2010) vol. 1, Article 15, 12 pages.
[cited by applicant]
Herschhorn et al., “Retroviral reverse transcriptases,” Cellular and Molecular Life Sciences (2010) vol. 67, pp. 2717-2747.
[cited by applicant]
Hockemeyer et al., “Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases,” Nature Biotechnology 27(9): 851-857, 2009.
[cited by applicant]
Holstein et al., Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors. Mol. Therapy., 2018, vol. 26(4): 1137-1153. (Year: 2018).
[cited by applicant]
Hwang et al., “Web-based design and analysis tools for CRISPR base editing,” BMC Bioinformatics (2018) vol. 19, Article 542, 7 pages.
[cited by applicant]
International Search Report and Written Opinion issued in PCT/US2019/048607 mailed on Jan. 15, 2020, 15 pages.
[cited by applicant]
Ivancevic et al., “LINEs between Species-Evolutionary Dynamics of LINE-1 Retrotransposons across the Eukaryotic Tree of Life,” Genome Biology and Evolution (2016) vol. 8, No. 11, pp. 3301-3322.
[cited by applicant]
Ivics et al., “Molecular Reconstruction of Sleeping Beauty, a Tc1-like Transposon from Fish, and Its Transposition in Human Cells,” Cell 1997, vol. 91, pp. 501-510.
[cited by applicant]
Jamburuthugoda et al., “The Reverse Transcriptase Encoded by the Non-LTR Retrotransposon R2 Is as Error-Prone as That Encoded by HIV-1,” Journal of Molecular Biology (2011).
[cited by applicant]
Jamburuthugoda et al., Identification of RNA binding motifs in the R2 retrotransposon-encoded reverse transcriptase, Nuc Acids Res (2014) vol. 42, No. 13, pp. 8405-8415.
[cited by applicant]
Jinek et al., “A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity,” Science (2012) vol. 337, pp. 816-821 and Supplementary Materials.
[cited by applicant]
Jurka et al., “Sequence patterns indicate an enzymatic involvement in integration of mammalian retroposons,” Proceedings of the National Academy of Sciences (1997) vol. 94, pp. 1872-1877.
[cited by applicant]
Kajikawa et al., “A new mechanism to ensure integration during LINE retrotransposition—A suggestion from analyses of the 5? extra nucleotides,” Gene (2012) vol. 505, pp. 345-351.
[cited by applicant]
Kawashima et al., “A novel target-specific gene delivery system combining baculovirus and sequence-specific long interspersed nuclear elements,” Virus Research (2007) vol. 127, pp. 49-60.
[cited by applicant]
Kelley et al., “The Phyre2 web portal for protein modeling, prediction and analysis,” Nature Protocols (2015) vol. 10, No. 6, pp. 845-858.
[cited by applicant]
Kierzek et al., “Secondary structures for 5′ regions of R2 retrotransposon RNAs reveal a novel conserved pseudoknot and regions that evolve under different constraints,” J Mol Biol (2009) vol. 390, No. 3, pp. 428-442.
[cited by applicant]
Kleinstiver et al., “Engineered CRISPR-Cas9 nucleases with altered PAM specificities,” Nature (2015) vol. 523, pp. 481-485.
[cited by applicant]
Klompe et al., “Transposon-encoded CRISPR-Cas systems direct RNA-guided DNA integration,” Nature (2019) vol. 571, No. 7764, pp. 219-225.
[cited by applicant]
Kojima et al., “The Wide Distribution and Change of Target Specificity of R2 Non-LTR Retrotransposons in Animals,” PLOS One (2016) vol. 11, No. 9, Article e0163496, 16 pages.
[cited by applicant]
Kojima et al., Recent Expansion of a New Ingi-Related Clade of Vingi non-LTR Retrotransposons in Hedgehogs, Molecular Biology and Evolution (2011) vol. 28, No. 1, pp. 17-20.
[cited by applicant]
Komor et al., “Programmable editing of a target base in genomic DNA without double-stranded DNA cleavag,” Nature (2016) vol. 523, pp. 420-424.
[cited by applicant]
Krzywkowski et al., “Limited reverse transcriptase activity of phi29 DNA polymerase,” Nucleic Acids Research (2018) vol. 46, No. 7, pp. 3625-3632.
[cited by applicant]
Kuroki-Kami et al., “Targeted gene knockin in zebrafish using the 28S rDNA-specific non-LTR-retrotransposon R201,” Mobile DNA (2019) vol. 10, Article 23, 12 pages.
[cited by applicant]
Kurzynska-Kokorniak et al., “DNA-directed DNA Polymerase and Strand Displacement Activity of the Reverse Transcriptase Encoded by the R2 Retrotransposon,” Journal of Molecular Biology (2007) vol. 374, pp. 322-333.
[cited by applicant]
Landrum et al., “ClinVar: public archive of interpretations of clinically relevant variants,” Nucleic Acids Research (2015) vol. 44, pp. D862-D868.
[cited by applicant]
Larson et al., “Spliced integrated retrotransposed element (SpIRE) formation in the human genome,” PLoS Biology (2018) vol. 16, No. 3, Article e2003067, 37 pages.
[cited by applicant]
Lathe et al., “A single lineage of r2 retrotransposable elements is an active, evolutionarily stable component of the
[cited by applicant]
Letunic et al., “20 Years of the SMART protein domain annotation resource,” Nucleic Acids Research (2018) vol. 46, pp. D493-D496.
[cited by applicant]
Li et al., “A Review of the Structure, Preparation, and Application of NLCs, PNPs, and PLNs,” Nanomaterials 7, 122, 2017.
[cited by applicant]
Lim et al., “Specific insertions of zinc finger domains into Gag-Pol yield engineered retroviral vectors with selective integration properties,” PNAS (2010) vol. 107, No. 28, pp. 12475-12480.
[cited by applicant]
Liu et al., “Computational approaches for effective CRISPR guide RNA design and evaluation,” Computational and Structural Biotechnology Journal (2020): vol. 18, pp. 35-44.
[cited by applicant]
Longsworth et al., “Expanding the Enzymatic Activity of the programmable Endonuclease Cas9 in Zebrafish,” Rice University Master of Arts Thesis (2018) 42 pages.
[cited by applicant]
Luan et al., “RNA Template Requirements for Target DNA-Primed Reverse Transcription by the R2 Retrotransposable Element,” Molecular and Cellular Biology (1995) vol. 15, No. 7, pp. 3882-3891.
[cited by applicant]
Lubelsky et al., “Sequences enriched in Alu repeats drive nuclear localization of long RNAs in human cells,” Nature 555 (107-111), 2018.
[cited by applicant]
Mahbub et al., “Globular domain structure and function of restriction-like-endonuclease LINEs-similarities to eukaryotic splicing factor Prp8,” Mobile DNA (2017) vol. 8, Article 16, 15 pages.
[cited by applicant]
Templeton et al., “Improved DNA: liposome complexes for increased systemic delivery and gene expression,” Nature Biotech, 15:647-652, 1997.
[cited by applicant]
Thompson et al., “Independently derived targeting of the 28S rDNA by A- and D-clade R2 retrotransposons,” Mobile Genetic Elements (2011) vol. 1, pp. 29-37.
[cited by applicant]
Trevino et al., “Genome Editing Using Cas9 Nickases,” Methods in Enzymology, Eds. Doudna et al. (2014) vol. 546, Chapter 8, pp. 161-174.
[cited by applicant]
Truong et al., “Retrohoming of a Mobile Group II Intron in Human Cells Suggests How Eukaryotes Limit Group II Intron Proliferation,” PLoS Genetics (2015) vol. 11, No. 8, Article e1005422, 35 pages.
[cited by applicant]
U.S. Appl. No. 62/263,223, filed Oct. 2, 2015.
[cited by applicant]
U.S. Appl. No. 62/332,099, filed Apr. 13, 2016.
[cited by applicant]
Ustyantsev et al., “Convergence of retrotransposons in oomycetes and plants,” Mobile DNA (2017) vol. 8, Article 4, 11 pages.
[cited by applicant]
Wagstaff et al., “Molecular reconstruction of extinct LINE-1 elements and their interaction with nonautonomous elements,” Molecular Biology and Evolution (2013) 30(1): 88-99.
[cited by applicant]
Wallace et al., “L1 mobile element expression causes multiple types of toxicity,” Gene (2008) vol. 419, pp. 75-81.
[cited by applicant]
Wicker et al., “A unified classification system for eukaryotic transposable elements,” Nature Reviews Genetics (2007) vol. 8, pp. 973-982.
[cited by applicant]
Xiong et al., “Functional expression of a sequence-specific endonuclease encoded by the retrotransposon R2Bm,” Cell (1988) vol. 55, pp. 235-246.
[cited by applicant]
Xiong et al., “Origin and evolution of retroelements based upon their reverse transcriptase sequences,” The EMBO Journal (1990) vol. 9, No. 10, pp. 3353-3362.
[cited by applicant]
Xu et al., “Accuracy and efficiency define Bxb1 integrase as the best of fifteen candidate serine recombinases for the integration of DNA into the human genome,” BMC Biotechnology (2013) vol. 13, Article 87, 17 pages.
[cited by applicant]
Yang et al., “Identification and characterization of nuclear and nucleolar localization signals in 58-kDa microspherule protein (MSP58),” Journal of Biomedical Science (2015) vol. 22, Article 33, 15 pages.
[cited by applicant]
Yang et al., “Identification of the endonuclease domain encoded by R2 and other site-specific, non-long terminal repeat retrotransposable elements,” PNAS (1999) vol. 96, pp. 7487-7852.
[cited by applicant]
Yasukawa et al., “Next-generation sequencing-based analysis of reverse transcriptase fidelity,” Biochemical and Biophysical Research Communications (2017) vol. 492, pp. 147-153.
[cited by applicant]
Zhang et al., “A novel RNA motif mediates the strict nuclear localization of a long noncoding RNA,” Molecular and Cellular Biology 34, 2318-2329 (2014).
[cited by applicant]
Zhang et al., “Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9,” Molecular Therapy (2019) vol. 27, No. 4, pp. 735-746.
[cited by applicant]
Zhao et al., “An ultraprocessive, accurate reverse transcriptase encoded by a metazoan group II intron,” RNA (2018) 24: 183-195.
[cited by applicant]
Zhao et al., “Crystal structures of a group II intron maturase reveal a missing link in spliceosome evolution,” Nature Structural & Molecular Biology (2016) vol. 23, No. 6, pp. 558-567.
[cited by applicant]
Zhu et al., “The iCRISPR Platform for Rapid Genome Editing in Human Pluripotent Stem Cells,” Methods in Enzymology, Eds. Doudna et al. (2014) vol. 546, Chapter 11, pp. 215-250.
[cited by applicant]
Zimmerly et al., “A Group II Intron RNA Is a Catalytic Component of a DNA Endonuclease Involved in Intron Mobility,” Cell (1995) vol. 83, pp. 529-538.
[cited by applicant]
Zimmerly et al., “An Unexplored Diversity of Reverse Transcriptases in Bacteria,” Microbiology Spectrum (2015) vol. 3, No. 2, Article MDNA-0058-2014, 16 pages.
[cited by applicant]
Zimmerly et al., “Evolution of group II introns,” Mobile DNA (2015) vol. 6, Article 7, 19 pages.
[cited by applicant]
Zimmerman et al., “A Completely Reimplemented MPI Bioinformatics Toolkit with a New Hhpred Server at its Core,” J Mol Biol (2018) vol. 430, pp. 2237-2243.
[cited by applicant]
Zingler et al., “Analysis of 5′ junctions of human LINE-1 and Alu retrotransposons suggests an alternative model for 5′-end attachment requiring microhomology-mediated end-joining,” Genome Research (2005) vol. 15, pp. 7…
[cited by applicant]
63rd Fujihara Seminar, “A new horizon of retroposon research,” Jul. 31-Aug. 3, 2012, Kyoto, Japan, program booklet with abstracts, 90 pages.
[cited by applicant]
[No Author Listed] Invitrogen—“ProQuest Two-Hybrid System: A sensitive method for detecting protein-protein interactions,” User Manual, Version A (2005) 116 pages.
[cited by applicant]
[No Author Listed] Rice University Events Listing for Aug. 3, 2018: Thesis Defense by Gia Longsworth, “Expanding the Enzymatic Activity of the Programmable Endonuclease Cas9 in Zebrafish,” with Abstract, first posted on…
[cited by applicant]
Ade et al., “Evaluating different DNA binding domains to modulate L1 ORF2p-driven site-specific retrotransposition events in human cells,” Gene (2018) vol. 642, pp. 188-198.
[cited by applicant]
Altenbuchner, “Editing of the Bacillus subtilis Genome by the CRISPR-Cas9 System,” Applied and Environmental Microbiology (2016) vol. 82, No. 17, pp. 5421-5427.
[cited by applicant]
An et al., “Plug and play modular strategies for synthetic retrotransposons,” Methods (2009) vol. 49, pp. 227-235.
[cited by applicant]
Anand et al., “Structure based design of protein linkers for zinc finger nuclease,” FEBS Letters, 587:19, 2013.
[cited by applicant]
Anzalone et al., “Search-and replace genome editing without double-strand breaks or donor DNA,” Nature (2019) vol. 576, No. 7785, pp. 149-157.
[cited by applicant]
Babushok et al., “Progress in understanding the biology of the human mutagen LINE-1,” Human Mutation (2007) vol. 28, No. 6, pp. 527-539.
[cited by applicant]
Bailey et al., “The MEME Suite,” Nucleic Acids Research (2015) vol. 43, pp. W39-W49.
[cited by applicant]
Bao et al., “Repbase Update, a database of repetitive elements in eukaryotic genomes,” Mobile DNA (2015) vol. 6, Article 11, 6 pages.
[cited by applicant]
Barnes et al., “Recombinant R2 Retrotransposon for Targeted Integration of Large Genetic Cassettes into the Human Genome,” Molecular Therapy (2019) vol. 27, No. 4S1, Abstract 216, p. 109.
[cited by applicant]
Bateman et al., “UniProt-the universal protein knowledgebase,” Nucleic Acids Research (2017) vol. 45, pp. D158-D169.
[cited by applicant]
Belfort et al., “Group II Intron RNPs and Reverse Transcriptases-From Retroelements to Research Tools,” Cold Spring Harbor Perspectives in Biology (2019) 11:a032375, 17 pages.
[cited by applicant]
Benitez-Guijarro et al., “RNase H2, mutated in Aicardi-Goutieres syndrome, promotes LINE-1 retrotransposition,” The EMBO Journal (2018) vol. 37, Article e98506, 22 pages.
[cited by applicant]
Bibillo et al., “High Processivity of the Reverse Transcriptase from a Non-long Terminal Repeat Retrotransposon,” J Biol Chem (2002) vol. 277, No. 38, pp. 34836-34845.
[cited by applicant]
Bibillo et al., “The Reverse Transcriptase of the R2 Non-LTR Retrotransposon: Continuous Synthesis of cDNA on Non-continuous RNA Templates,” J Mol Biol (2002) vol. 316, pp. 459-473.
[cited by applicant]
Birbach et al., “Cytosolic, nuclear and nucleolar localization signals determine subcellular distribution and activity of the NF-kappaB inducing kinase NIK,” Journal of Cell Science, 117 (3615-3624), 2004.
[cited by applicant]
Bodea et al., “Retrotransposon-induced mosaicism in the neural geome,” Open Biology (2018) vol. 8, No. 7, Article 180074, 17 pages.
[cited by applicant]
Boissinot et al., “L1 (LINE-1) Retrotransposon Evolution and Amplification in Recent Human History,” Molecular Biology and Evolution 2000, 915-928.
[cited by applicant]
Bono et al., “Connecting genotypes, phenotypes and fitness: harnessing the power of CRISPR/Cas9 genome editing,” Molecular Ecology (2015) vol. 24, pp. 3810-3822.
[cited by applicant]
Burke et al., “R4, a non-LTR retrotransposon specific to the large subunit rRNA genes of nematodes,” Nucleic Acids Res. 23, 4628-34 (1995).
[cited by applicant]
Burke et al., “Sequence relationship of retrotransposable elements R1 and R2 within and between divergent insect species,” Molecular Biology and Evolution (1993) vol. 10, No. 1, pp. 163-185.
[cited by applicant]
Burke et al., “The domain structure and retrotransposition mechanism of R2 elements are conserved throughout arthropods,” Molecular Biology and Evolution (1999) vol. 16, No. 4, pp. 502-511.
[cited by applicant]
Candales et al., “Database for bacterial group II introns,” Nucleic Acids Research (2012) vol. 40, pp. D187-D190.
[cited by applicant]
Chan et al., “Crystal structure of a group II intron in the pre-catalytic state,” Nature Structural & Molecular Biology (2012) vol. 19, No. 5, pp. 555-557.
[cited by applicant]
Chen et al., “Fusion Protein Linkers: Property, Design and Functionality,” Adv Drug Deliv Rev (2013) 65(10): 1357-1369.
[cited by applicant]
Chillón et al., “In vitro characterization of the splicing efficiency and fidelity of the RmInt1 group II intron as a means of controlling the dispersion of its host mobile element,” RNA (2014) vol. 20, No. 12, pp. 2000…
[cited by applicant]
Choi et al., “Interplay between RNASEH2 and MOV10 controls LINE-1 retrotransposition,” Nucleic Acids Research (2018) doi: 10/1093/nar/gkx1312, 15 pages.
[cited by applicant]
Choudhuri, “Bioinformatics for Beginners: Genes, Genomes, Molecular Evolution, Databases and Analytical Tools,” Elsevier (2014) p. 64.
[cited by applicant]
Christensen et al., “Footprint of the Retrotransposon R2Bm Protein on its Target Site Before and After Cleavage,” Journal of Molecular Biology (2004) vol. 336, No. 5, pp. 1035-1045.
[cited by applicant]
Christensen et al., “R2 Target-Primed Reverse Transcription-Ordered Cleavage and Polymerization Steps by Protein Subunits Asymmetrically Bound to the Target DNA,” Molecular and Cellular Biology (2005) vol. 25, No. 15, p…
[cited by applicant]
Christensen et al., “RNA from the 5′ end of the R2 retrotransposon controls R2 protein binding to and cleavage of its DNA target site,” Proceedings of the National Academy of Sciences (2006) vol. 103, No. 47, pp. 17602-…
[cited by applicant]
Christensen et al., “Role of the Bombyx mori R2 element N-terminal domain in the target-primed reverse transcription (TPRT) reaction,” Nucleic Acids Research (2005) vol. 33, No. 20, pp. 6461-6468.
[cited by applicant]
Cordaux et al., “The impact of retrotransposons on human genome evolution, ”Nature Reviews Genetics (2009) Nature Reviews vol. 10, pp. 691-703.
[cited by applicant]
Cost et al., “Targeting of Human Retrotransposon Integration Is Directed by the Specificity of the L1 Endonuclease for Regions of Unusual DNA Structure,” Biochemistry (1998) vol. 37, pp. 18081-18093.
[cited by applicant]
Craig et al., Editors, “Mobile Dna III,” ASM Press (2015) pp. 1-1346.
[cited by applicant]
Denli et al., “Primate-Specific ORF0 Contributes to Retrotransposon-Mediated Diversity,” Cell (2015) vol. 163, No. 3, pp. 583-593.
[cited by applicant]
Dewannieux et al., “Role of poly(A) tail length in Alu retrotransposition,” Genomics (2005) vol. 86, pp. 378-381.
[cited by applicant]
Doucet et al., “A 3′ Poly(A) Tract Is Required for LINE-1 Retrotransposition,” Molecular Cell (2015) vol. 60, pp. 728-741.
[cited by applicant]
Eickbush et al., “Integration of Bombyx mori R2 Sequences into the 28S Ribosomal RNA Genes of
[cited by applicant]
Eickbush et al., “Integration, Regulation, and Long-Term Stability of R2 Retrotransposons,” Microbiology Spectrum (2015) vol. 3, No. 2, MDNA3-011, 20 pages.
[cited by applicant]
Eickbush et al., “R2 and R2-R1 hybrid non-autonomous retrotransposons derived by internal deletions of full-length elements,” Mobile DNA (2012) vol. 3, Article 10, 15 pages.
[cited by applicant]
Eickbush et al., “R2 Retrotransposons Encode a Self-Cleaving Ribozyme for Processing from an rRNA Cotranscript,” Molecular and Cellular Biology (2010) vol. 30, No. 13, pp. 3142-3150.
[cited by applicant]
Ellefson et al., “Synthetic evolutionary origin of a proofreading reverse transcriptase,” Science (2016) vol. 352, Issue 6293, pp. 1590-1593.
[cited by applicant]
Enyeart et al., “Biotechnological applications of mobile group II introns and their reverse transcriptases-gene targeting, RNA-seq, and non-coding RNA analysis,” Mobile DNA (2014) vol. 5, Article 2, 19 pages.
[cited by applicant]
Faure et al., “CRISPR-Cas in mobile genetic elements: counter-defence and beyond,” Nat Rev Microbiol (2019) vol. 17, No. 8, pp. 513-525.
[cited by applicant]
Finn et al., “InterPro in 2017—beyond protein family and domain annotations,” Nucleic Acids Res (2017) vol. 45, No. D1, pp. D190-D199.
[cited by applicant]
Finnegan, “Transposable elements—How non-LTR retrotransposons do it,” Current Biology (1997) vol. 7, pp. R245-R248.
[cited by applicant]
Flasch et al., “Genome-wide de novo L1 Retrotransposition Connects Endonuclease Activity with Replication,” Cell (2019) vol. 177, p. 877-851.
[cited by applicant]
Maita et al., “Crystal Structure of the Endonuclease Domain Encoded by the Telomere-specific Long Interspersed Nuclear Element, TRAS1,” Journal of Biological Chemistry (2004) vol. 279, No. 39, p. 41607-41076.
[cited by applicant]
Malik et al., “Ribonuclease H evolution in retrotransposable elements,” Cytogenetic and Genome Research (2005) vol. 110, pp. 392-401.
[cited by applicant]
Mastroianni et al., “Group II Intron-Based Gene Targeting Reactions in Eukaryotes,” PLoS ONE (2008) vol. 3, Issue 9, Article e3121, 15 pages.
[cited by applicant]
Meers et al., “DNA repair by RNA: Templated, or not templated, that is the question,” DNA Repair (2016) vol. 44, pp. 17-21.
[cited by applicant]
Mills et al., “Which transposable elements are active in the human genome,” Trends in Genetics (2007) vol. 23, No. 4, pp. 183-191.
[cited by applicant]
Mita et al., “LINE-1 protein localization and functional dynamics during the cell cycle, ”eLife (2018) vol. 7, Article e30058, 35 pages.
[cited by applicant]
Miyagawa et al.,“ Identification of cis- and trans-acting factors involved in the localization of MALAT-1 noncoding RNA to nuclear speckles,” RNA (2012) vol. 18, pp. 738-751.
[cited by applicant]
Miyoshi et al., “Poly(ADP-Ribose) Polymerase 2 Recruits Replication Protein A to Sites of LINE-1 Integration to Facilitate Retrotransposition,” Molecular Cell (2019) vol. 75, pp. 1286-1298.
[cited by applicant]
Mohr et al., “A Reverse Transcriptase-Cas1 Fusion Protein Contains a Cas6 Domain Required for Both CRISPR RNA Biogenesis and RNA Spacer Acquisition,” Molecular Cell (2018) vol. 72 pp. 700-714.
[cited by applicant]
Moran et al., “High Frequency Retrotransposition in Cultured Mammalian Cells,” Cell (1996) vol. 87, pp. 917-927.
[cited by applicant]
Moss et al., “The R2 retrotransposon RNA families,” RNA Biology (2011) vol. 8, No. 5, pp. 714-718.
[cited by applicant]
Mukha et al., “Endonuclease domain of the
[cited by applicant]
Naldini et al., “In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector” Science (1996) vol. 272 pp. 263-267.
[cited by applicant]
Nami et al., “Strategies for In Vivo Genome Editing in Nondividing Cells,” Trends in Biotechnology (2018) vol. 36, No. 8, pp. 770-786.
[cited by applicant]
Nichuguti et al., “Both the Exact Target Site Sequence and a Long Poly(A) Tail Are Required for Precise Insertion of the 18S Ribosomal DNA-Specific Non-Long Terminal Repeat Retrotransposon R7Ag,” Molecular and Cellular …
[cited by applicant]
Nuñez et al., “Cas1-Cas2 complex formation mediates spacer acquisition during CRISPR-Cas adaptive immunity,” Nature Structural & Molecular Biology (2014) vol. 21, No. 6, pp. 528-534.
[cited by applicant]
Opposition Brief filed in European Patent No. 3448990, mailed Mar. 15, 2022, 66 pages.
[cited by applicant]
Osanai et al., “Essential Motifs in the 3′ Untranslated Region Required for Retrotransposition and the Precise Start of Reverse Transcription in Non-Long-Terminal-Repeat Retrotransposon SART1,” Molecular and Cellular Bi…
[cited by applicant]
Ostertag et al., “Biology of Mammalian L1 Retrotransposons” Annual Review of Genetics (2001) vol. 35, pp. 501-538.
[cited by applicant]
Ostertag et al., “Twin Priming—A Proposed Mechanism for the Creation of Inversions in L1 Retrotransposition,” Genome Research (2001) vol. 11, pp. 2059-2065.
[cited by applicant]
Paix et al., “Scalable and Versatile Genome Editing Using Linear DNAs with Microhomology to Cas9 Sites in Caenorhabditis elegans,” Genetics (2014) vol. 198, pp. 1347-1356.
[cited by applicant]
Pei et al., “PROMALS3D—a tool for multiple protein sequence and structure alignments,” Nucleic Acids Research (2008) vol. 36, No. 7, pp. 2295-2300.
[cited by applicant]
Pellenz et al., “New human chromosomal safe harbor sites for genome engineering with CRISPR/Cas9, TAL effector and homing endonucleases,” Human Gene Therapy (2018) doi: 10.1101/396390, 39 pages.
[cited by applicant]
Peters et al., “Recruitment of CRISPR-Cas systems by Tn7-like transposons,” PNAS (2017) vol. 114, No. 35, pp. E7358-E7366.
[cited by applicant]
Piskareva et al., “The carboxy-terminal segment of the human LINE-1 ORF2 protein is involved in RNA binding,” FEBS Open Bio (2013) vol. 3, pp. 433-437.
[cited by applicant]
Qu et al., “Structure of a group II intron in complex with its reverse transcriptase,” Nature Structural & Molecular Biology (2016) vol. 23, No. 6, pp. 549-557.
[cited by applicant]
Ran et al., “Genome engineering using the CRISPR/Cas9 system,” Nature Protocols (2013) vol. 8, No. 11, pp. 2281-2308.
[cited by applicant]
Ruminski et al., “Processing and Translation Initiation of Non-long Terminal Repeat Retrotransposons by Hepatitis Delta Virus (HDV)-like Self-cleaving Ribozymes,” J Biol Chem (2011) vol. 286, No. 48, pp. 41286-41295.
[cited by applicant]
Ruschak et al. “Secondary structure models of the 3′ untranslated regions of diverse R2 RNAs” RNA (2004) vol. 10(6): 978-987.
[cited by applicant]
San Filippo et al., “Characterization of the C-Terminal DNA-binding-DNA Endonuclease Region of a Group II Intron-encoded Protein,” Journal of Molecular Biology (2002) vol. 324, pp. 933-951.
[cited by applicant]
Sano et al., “Mutations to create thermostable reverse transcriptase with bacterial family A DNA polymerase from Thermotoga petrophila K4,” Journal of Bioscience and Bioengineering (2012) vol. 113, No. 3, pp. 315-321.
[cited by applicant]
Sharma et al., “In vivo genome editing of the albumin locus as a platform for protein; replacement therapy,” Blood (2015) vol. 126, No. 15: 1777-1784.
[cited by applicant]
Sharon et al., “Functional Genetic Variants Revealed by Massively Parallel Precise Genome Editing,” Cell (2018) vol. 175, pp. 544-557.
[cited by applicant]
Shivram et al., “Targeting novel sites: The N-terminal DNA binding domain of non-LTR retrotransposons is an adaptable module that is implicated in changing site specificities,” Mobile Genetic Elements (2011) vol. 1, No.…
[cited by applicant]
Shukla et al., “High-throughput identification of RNA nuclear enrichment sequences,” The EMBO Journal (2018) vol. 37, Article e98452, 11 pages.
[cited by applicant]
Silas et al., Direct CRISPR spacer acquisition from RNA by a natural reverse-transcriptase-Cas1 fusion protein, Science (2016) vol. 351, No. 6276, Article aad4234, 31 pages.
[cited by applicant]
Simon et al., “Retrons and their applications in genome engineering,” Nucleic Acids Research (2019) doi: 10.1093/ narlgkz865, 13 pages.
[cited by applicant]
Smyshlyaev et al., “Acquisition of an Archaea-like ribonuclease H domain by plant L1 retrotransposons supports modular evolution,” Proceedings of the National Academy of Sciences (2013) vol. 110, No. 50, p. 20140-20145.
[cited by applicant]
Spuch and Navarro, “Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease),” Journal of Drug Delivery, vol. 2011, Article ID 469679, 12 p. 2011.…
[cited by applicant]
Stamos et al., “Structure of a Thermostable Group II Intron Reverse Transcriptase with Template-Primer and Its Functional and Evolutionary Implications,” Molecular Cell (2017) vol. 68, pp. 926-939.
[cited by applicant]
Strecker et al., “RNA-guided DNA insertion with CRISPR-associated transposases,” Science (2019) vol. 365, No. 6448, pp. 48-53.
[cited by applicant]
Su et al., “Human DNA polymerase [eta] has reverse transcriptase activity in cellular environments,” J Biol Chem (2019) vol. 294, No. 15, pp. 6073-6081.
[cited by applicant]
Su et al., “Sequence-specific retrotransposition of 28S rDNA-specific Line R2OI in human cells” RNA (2019 ) vol. 25, pp. 1432-1438.
[cited by applicant]
Sultana et al., “Integration site selection by retroviruses and transposable elements in eukaryotes,” Nature Reviews Genetics (2017) doi: 10.1038/nrg.2017.7, 17 pages.
[cited by applicant]
Sultana et al., “The Landscape of L1 Retrotransposons in the Human Genome Is Shaped by Pre-insertion Sequence Biases and Post-insertion Selection,” Molecular Cell (2019) vol. 74, pp. 555-570.
[cited by applicant]
Sultana T., Influence of the genomic context on integration site selection by human L 1 retrotransposons. Ph.D. Dissertation, 2016, Universite Cote D'Azur, France, pp. 1-184. (Year: 2016).
[cited by applicant]
Takahashi et al., “Transplantation of target site specificity by swapping the endonuclease domains of two LINES,” The EMBO Journal (2002) vol. 21, No. 3, pp. 408-417.
[cited by applicant]
Takasu et al., “Targeted mutagenesis in the silkworm Bombyx mori using zinc finger nuclease mRNA injection,” Insect Biochemistry and Molecular Biology 40(10): 759-765, 2010.
[cited by applicant]
Tang et al., “Rewritable multi-event analog recording in bacterial and mammalian cells,” Science (2018) vol. 360, No. 6385, eaap8992.
[cited by applicant]
Taylor et al., “Affinity Proteomics Reveals Human Host Factors Implicated in Discrete Stages of LINE-1 Retrotransposition,” Cell (2013) vol. 155, pp. 1034-1048.
[cited by applicant]
Luo et al., “Comparative analysis of chimeric ZFP-, TALE- and Cas9-piggyBac transposases for integration into a single locus in human cells,” Nucleic Acids Research (2017) vol. 45, No. 14, pp. 8411-8422.
[cited by applicant]